| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/05/2009 | WO2009017625A1 Treatment of depression, phychosis, and anxiety |
| 02/05/2009 | WO2009017455A1 A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| 02/05/2009 | WO2009017454A1 New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| 02/05/2009 | WO2009017453A1 New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| 02/05/2009 | WO2009017452A1 New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate |
| 02/05/2009 | WO2009017236A1 Pyridopyrimidin-4-one derivatives |
| 02/05/2009 | WO2009017219A1 Inhibitor of binding of s1p1 |
| 02/05/2009 | WO2009017161A1 Inhibitory agent for inflammatory cytokine |
| 02/05/2009 | WO2009016643A1 Process for the preparation glatiramer acetate (copolymer-1) |
| 02/05/2009 | WO2009016564A2 2-aza-bicyclo[3.3.0]octane derivatives |
| 02/05/2009 | WO2009016560A2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| 02/05/2009 | WO2009016414A1 Novel process |
| 02/05/2009 | WO2009016384A2 Gsk-3 inhibitors |
| 02/05/2009 | WO2009016329A1 Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions |
| 02/05/2009 | WO2009016286A2 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof |
| 02/05/2009 | WO2009016241A1 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators |
| 02/05/2009 | WO2009016227A2 Novel compounds |
| 02/05/2009 | WO2009016225A1 1-piperidinyl-6-piperidinylsulfonylindoles as 5-ht (2b) receptor antagonists |
| 02/05/2009 | WO2009016178A1 Methods and substances for the treatment of alzheimer's |
| 02/05/2009 | WO2009016088A1 The use of benzamide derivatives for the treatment of cns disorders |
| 02/05/2009 | WO2009016087A1 Monoamide derivatives as orexin receptor antagonists |
| 02/05/2009 | WO2009016085A1 Spiro compounds useful as antagonists of the h1 receptor |
| 02/05/2009 | WO2009016084A1 Spiro cyclopentane compounds useful as antagonists of the h1-receptor |
| 02/05/2009 | WO2009016069A2 Stable liquid pharmaceutical composition based on trazodone |
| 02/05/2009 | WO2009016048A1 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| 02/05/2009 | WO2009015867A1 Substituted aryl or heteroarylpiperdine derivatives as melanocortin-4 receptor modulators |
| 02/05/2009 | WO2009015844A1 Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| 02/05/2009 | WO2009015828A1 Paliperidone derivatives |
| 02/05/2009 | WO2009015812A2 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile |
| 02/05/2009 | WO2009015667A1 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
| 02/05/2009 | WO2009015454A1 Composition and manufacturing process of calming and sleep facilitator product |
| 02/05/2009 | WO2008153958A3 Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| 02/05/2009 | WO2008137134A3 Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide |
| 02/05/2009 | WO2008135826A3 2 -pyridine carboxamide derivatives as sodium channel modulators |
| 02/05/2009 | WO2008129054A3 Heterocyclic compounds with affinity to muscarinic receptors |
| 02/05/2009 | WO2008128919A3 Histamine h3 receptor ligands comprising a cyclobutoxy group |
| 02/05/2009 | WO2008122654A3 Use of hyperbaric conditions to provide neuroprotection |
| 02/05/2009 | WO2008108957A3 Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain |
| 02/05/2009 | WO2008047951A3 An alzheimer' s disease progression inhibitor containing heterocyclic compound |
| 02/05/2009 | WO2003099808A8 Substituted heterocyclic compounds and methods of use |
| 02/05/2009 | US20090036822 Electrotransport Agent Delivery Method and Apparatus |
| 02/05/2009 | US20090036682 Crystalline form of 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; used in the treatment of CNS and other disorders |
| 02/05/2009 | US20090036542 Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same |
| 02/05/2009 | US20090036540 Guanylhydrazones in Methods of Treatment or Diagnosis as Modulators of Signal Transduction |
| 02/05/2009 | US20090036532 DHA Enrichment Process |
| 02/05/2009 | US20090036529 Therapeutic agent for functional brain disease |
| 02/05/2009 | US20090036521 Process for Production of Optically Active Amine Derivatives |
| 02/05/2009 | US20090036495 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
| 02/05/2009 | US20090036493 Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex |
| 02/05/2009 | US20090036488 Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
| 02/05/2009 | US20090036482 Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| 02/05/2009 | US20090036480 5-Ht7 Receptor Antagonists |
| 02/05/2009 | US20090036478 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| 02/05/2009 | US20090036477 Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors |
| 02/05/2009 | US20090036476 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 02/05/2009 | US20090036475 Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| 02/05/2009 | US20090036471 Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors |
| 02/05/2009 | US20090036470 Paliperidone derivatives |
| 02/05/2009 | US20090036468 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| 02/05/2009 | US20090036461 Use of Azabicyclo Hexane Derivatives |
| 02/05/2009 | US20090036456 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 02/05/2009 | US20090036455 Arylpiperazine derivative and use thereof as 5-ht1a receptor ligands |
| 02/05/2009 | US20090036454 Compounds and Uses Thereof |
| 02/05/2009 | US20090036442 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 02/05/2009 | US20090036436 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity |
| 02/05/2009 | US20090036427 Substituted bicyclic pyrimidone derivatives |
| 02/05/2009 | US20090036420 Benzamide derivatives and their use for treating cns disorders |
| 02/05/2009 | US20090036419 Compounds useful as raf kinase inhibitors |
| 02/05/2009 | US20090036411 Modulation of cell fates and activities by phthalazinediones |
| 02/05/2009 | US20090036406 Injection |
| 02/05/2009 | US20090036405 Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| 02/05/2009 | US20090036400 Pharmaceutical Preparations for Treating the Consequences of Alcohol Abuse, Hepatitis, Pancreatitis, Alzheimer's Disease, Parkinson's Disease, Diabetes, Toxic Kidney Disease, Reperfusion Damage, Arteriosclerosis, and as an Antidote Against Environmental Toxins and Medicinal Intoxication |
| 02/05/2009 | US20090036395 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 02/05/2009 | US20090036393 Vesicular monoamine transporter gene therapy in Parkinson's disease |
| 02/05/2009 | US20090036379 Inhibitors of proteins from the rho-gef family |
| 02/05/2009 | US20090036376 Treatment for Anxiety |
| 02/05/2009 | US20090036360 Medicament containing activated antithrombin iii |
| 02/05/2009 | US20090036359 Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses |
| 02/05/2009 | US20090035370 Dosage form and method of use |
| 02/05/2009 | US20090035357 Method of drug delivery using a transdermal device having a phase change material |
| 02/05/2009 | US20090035307 Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES |
| 02/05/2009 | US20090035302 Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith |
| 02/05/2009 | US20090035295 Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies |
| 02/05/2009 | US20090035285 Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs |
| 02/05/2009 | US20090035284 Derivation of neural stem cells from embryonic stem cells and methods of use thereof |
| 02/05/2009 | US20090035282 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 02/05/2009 | US20090035256 Modified interleukin 10 polypeptide for use in treatment and prevention of neuropathic pain, neurological and inflammatory disorders |
| 02/05/2009 | US20090035217 Truncated Fragments of Alpha-Synuclein in Lewy Body Disease |
| 02/05/2009 | DE19963179B4 Substituierte 1- und 2-Naphthol-Mannichbasen Substituted 1- and 2-naphthol Mannich bases |
| 02/05/2009 | CA2723139A1 Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| 02/05/2009 | CA2719824A1 Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| 02/05/2009 | CA2705046A1 Process for the preparation glatiramer acetate (copolymer-1) |
| 02/05/2009 | CA2698170A1 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile |
| 02/05/2009 | CA2695196A1 Naphthyridine derivatives as potassium channel modulators |
| 02/05/2009 | CA2695071A1 The use of benzamide derivatives for the treatment of cns disorders |
| 02/05/2009 | CA2694887A1 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
| 02/05/2009 | CA2694762A1 Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| 02/05/2009 | CA2694663A1 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators |
| 02/05/2009 | CA2694608A1 A process for the preparation of almotriptan and a synthetic intermediate usable in said process |
| 02/05/2009 | CA2694510A1 Treatment with .alpha.7-selective ligands |